Edition:
India

bluebird bio Inc (BLUE.OQ)

BLUE.OQ on NASDAQ Stock Exchange Global Select Market

170.45USD
26 Apr 2018
Change (% chg)

$7.85 (+4.83%)
Prev Close
$162.60
Open
$164.20
Day's High
$170.85
Day's Low
$163.05
Volume
117,704
Avg. Vol
251,131
52-wk High
$236.05
52-wk Low
$74.65

Select another date:

Wed, Mar 28 2018

BRIEF-Bluebird Bio And Celgene Corporation To Co-Develop Anti-Bcma Car T Cell Therapy Bb2121 In The U.S.

* BLUEBIRD BIO AND CELGENE CORPORATION ENTER INTO AGREEMENT TO CO-DEVELOP AND CO-PROMOTE ANTI-BCMA CAR T CELL THERAPY BB2121 IN THE UNITED STATES

BRIEF-Bluebird Bio Reports Q4 Loss Per Share $2.52‍​

* BLUEBIRD BIO REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS

BRIEF-Celgene Says Bluebird Car-T Therapy Remains A Top Priority

* CELGENE CEO SAYS WORKING WITH BLUEBIRD BIO TO DEVELOP BB2121 CAR-T THERAPY FOR MYELOMA REMAINS A TOP PRIORITY

Bluebird to seek approvals for three treatments by end of 2019

U.S. biotech bluebird bio Inc, which does not yet have any marketed products, expects to be able to file for regulatory approval of three novel treatments by the end of 2019, chief executive Nick Leschly announced on Tuesday.

CORRECTED-Bluebird to seek approvals for three treatments by end of 2019

Jan 9 U.S. biotech bluebird bio Inc, which does not yet have any marketed products, expects to be able to file for regulatory approval of three novel treatments by the end of 2019, chief executive Nick Leschly announced on Tuesday.

BRIEF-Bluebird Bio Expects Three Regulatory Filings By End 2019

* BLUEBIRD BIO CEO SAYS EXPECTS THREE REGULATORY FILINGS BY END 2019

BRIEF-Merck And Bluebird Bio Sign Supply Agreement For Commercial Production Of Viral Vectors

* MERCK AND BLUEBIRD BIO SIGN SUPPLY AGREEMENT FOR COMMERCIAL PRODUCTION OF VIRAL VECTORS Source text - http://bit.ly/2DfAvDy Further company coverage: (Gdynia Newsroom)

BRIEF-Bluebird Bio Prices Public Offering Of 3.2 Mln Shares At $185/Share

* BLUEBIRD BIO ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Bluebird Bio Announces Proposed Public Offering Of Common Stock

* BLUEBIRD BIO ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-bluebird bio And TC BioPharm Announce Strategic Collaboration

* BLUEBIRD BIO AND TC BIOPHARM ANNOUNCE STRATEGIC COLLABORATION TO RESEARCH AND DEVELOP GAMMA DELTA CAR T CELL PRODUCT CANDIDATES FOR CANCER IMMUNOTHERAPY

Select another date: